Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.52 |
| ▸ | GAA | P10253 | 7/20 | 0.52 |
| ▸ | MEN1 | O00255 | 6/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | THRB | P10828 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 6/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 4/20 | 0.41 |
| ▸ | SENP6 | Q9GZR1 | 4/20 | 0.41 |
| ▸ | CASP3 | P42574 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL427798 | 1.00 | MAPT (0.52) | MAPTGAAMEN1KMT2ALMNA | |
| SCHEMBL4400056 | 1.00 | MAPT (0.52) | MAPTGAAMEN1KMT2ALMNA | |
| SCHEMBL4406701 | 0.90 | MAPT (0.46) | MAPTGAAMEN1KMT2ALMNA | |
| SCHEMBL427103 | 0.90 | MAPT (0.46) | MAPTGAAMEN1KMT2ALMNA | |
| SCHEMBL427102 | 0.90 | MAPT (0.46) | MAPTGAAMEN1KMT2ALMNA | |
| SCHEMBL429009 | 0.88 | MAPT (0.44) | MAPTGAAMEN1KMT2ALMNA | |
| SCHEMBL429010 | 0.88 | MAPT (0.44) | MAPTGAAMEN1KMT2ALMNA | |
| SCHEMBL2671834 | 0.85 | MAPT (0.50) | MAPTGAAMEN1KMT2ALMNA | |
| SCHEMBL4400051 | 0.85 | MAPT (0.50) | MAPTGAAMEN1KMT2ALMNA | |
| SCHEMBL2671836 | 0.85 | MAPT (0.50) | MAPTGAAMEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1687004-A4 | PYRIDINE COMPOUNDS | SYNTA PHARMACEUTICALS CORP (US) | 2009-04-08 | — | — | EP | claimed |
| JP-2007510747-A | — | — | 2007-04-26 | — | — | JP | claimed |
| EP-1687004-A2 | PYRIDINE COMPOUNDS | Synta Pharmaceuticals Corporation (US) | 2006-08-09 | — | — | EP | claimed |
| US-20050250774-A1 | Pyridine compounds | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2005-11-10 | — | — | US | claimed |
| WO-2005046603-A2 | PYRIDINE COMPOUNDS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-05-26 | — | — | WO | claimed |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-25 | — | — | US | disclosed |
| US-8173651-B2 | Pyridine compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2012-05-08 | — | — | US | disclosed |
| US-20120021434-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-04-28 | — | — | US | disclosed |
| US-20100173413-A1 | PYRIDINE COMPOUNDS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2010-07-08 | — | — | US | disclosed |
| US-7687498-B2 | Pyridine compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2010-03-30 | — | — | US | disclosed |
| US-20090163708-A1 | PROCESS FOR PREPARING MESYLATE SALTS OF IL-12 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2009-06-25 | — | — | US | disclosed |
| US-20080167300-A1 | PYRIDINE COMPOUNDS | MADRIGAL PHARMACEUTICALS, INC. | 2008-07-10 | — | — | US | disclosed |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167300-A1 | PYRIDINE COMPOUNDS | IL2, IL4, IL6 | MAPT 1165/4885GAA 841/4885MEN1 2681/4885 |
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | IL17A, IL23R, IL15 | MAPT 238/4885GAA 2575/4885MEN1 4796/4885 |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | REL, NFATC1, BCL6 | MAPT 4316/4885GAA 3596/4885MEN1 3751/4885 |
| US-20100173413-A1 | PYRIDINE COMPOUNDS | IL2, IL4, IL6 | MAPT 1165/4885GAA 841/4885MEN1 2681/4885 |
| US-20050250774-A1 | Pyridine compounds | IL2, IL4, IL6 | MAPT 1165/4885GAA 841/4885MEN1 2681/4885 |
| US-20090163708-A1 | PROCESS FOR PREPARING MESYLATE SALTS OF IL-12 INHIBITORY COMPOUNDS | IL17A, IL23R, IL2 | MAPT 2815/4885GAA 2317/4885MEN1 293/4885 |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | REL, NFATC1, BCL6 | MAPT 4316/4885GAA 3596/4885MEN1 3751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.